Female sexual dysfunction and the central nervous system

Journal of Sexual Medicine

Volumn 4, Issue SUPPL. 4, 2007, Pages 257-259

  Perelman, Michael A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREMELANOTIDE; CENTRAL NERVOUS SYSTEM AGENTS; DOPAMINE; MELANOCORTIN; N ACETYLNORLEUCYLASPARTYLHISTIDYL DEXTRO PHENYLALANYLARGINYLTRYPTOPHYLLYSINE 2,7 CYCLIC AMIDE; PHOSPHODIESTERASE V INHIBITOR; SEROTONIN; TESTOSTERONE; UNCLASSIFIED DRUG;

BEHAVIOR THERAPY; BLOOD VESSEL FUNCTION; CENTRAL NERVOUS SYSTEM FUNCTION; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG MECHANISM; EDITORIAL; FEMALE; FEMALE SEXUAL DYSFUNCTION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GROUP THERAPY; HORMONE RECEPTOR INTERACTION; HORMONE RESPONSE; HUMAN; MALE SEXUAL DYSFUNCTION; MONOTHERAPY; PATIENT COUNSELING; PRIORITY JOURNAL; PROTEIN FUNCTION; SEX THERAPY; SEXUAL AROUSAL; SEXUAL BEHAVIOR; TREATMENT OUTCOME;

EID: 35648930964     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2007.00608.x     Document Type: Article

References (28)

1. Fourcroy JL. Female sexual dysfunction: Potential for pharmacotherapy. Drugs 2003; 63: 1445-57.
2. Nijland E, Davis S, Laan E, Schultz WW. Female sexual satisfaction and pharmaceutical intervention: A critical review of the drug intervention studies in female sexual dysfunction. J Sex Med 2006; 3: 763.
3. Goldstein I, Meston CM, Traish AM, Davis SR. Future directions. In: Goldstein I, Meston CM, Davis SR, Traish AM, eds. Women's sexual function and dysfunction: Study, diagnosis and treatment. London: Taylor & Francis; 2006: 745-8.
4. Kang D, Ducharme S. Integration of medical and psychologic diagnosis and treatment. In: Goldstein I, Meston CM, Davis SR, Traish AM, eds. Women's sexual function and dysfunction: Study, diagnosis and treatment. London: Taylor & Francis; 2006.
5. Perelman MA. Combination therapy for sexual dysfunction: Integrating sex therapy and pharmacotherapy. In: Balon R, Segraves RT, eds. Handbook of sexual dysfunction. Boca Raton: Taylor & Francis; 2005: 13-41.
6. Althof SE. Therapeutic weaving: The integration of treatment techniques. In: Levine SB, ed. Handbook of clinical sexuality for mental health professionals. New York: Brunner-Routledge; 2003: 359-76.
7. Halaris A. Neurochemical aspects of the sexual response cycle. CNS Spectr 2003; 8: 211-6.
8. Clayton A, Kornstein S, Prakash A, Mallinckrodt C, Wohlreich M. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med 2007; 4(Pt 1): 917-29.
9. Goldstein I. Current management strategies of the postmenopausal patient with sexual health problems. J Sex Med 2007; 4(3 suppl): 235-53.
10. Masters WH, Johnson VE. Human sexual inadequacy. Boston: Little Brown; 1970.
11. Kaplan HS. The new sex therapy. New York: Brunner/Mazel; 1974.
12. Heiman JR, Meston CM. Empirically validated treatment for sexual dysfunction. 1997; 148-94.
13. Imbimbo C, Gentile V, Palmieri A, Longo N, Fusco F, Granata AM, Verze P, Mirone V. Female sexual dysfunction: An update on physiopathology. J Endocrinol Invest 2003; 26(3 suppl): 102-4.
14. Park K, Moreland RB, Goldstein I, Atala A, Traish A. Sildenafil inhibits phosphodiesterase type 5 in human clitoral corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1998; 249: 612-7.
15. Berman JR, Berman LA, Toler SM, Gill J, Haughie S. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: A double-blind, placebo controlled study. J Urol 2003; 170(Pt 1): 2333-8.
16. Basson R, McInnes R, Smith MD, Hodgson G, Koppiker N. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med 2002; 11: 367-77.
17. Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 1987; 49: 397-409.
18. Bancroft J, Sherwin BB, Alexander GM, Davidson DW, Walker A. Oral contraceptives, androgens, and the sexuality of young women: II. The role of androgens. Arch Sex Behav 1991; 20: 121-35.
19. Alexander GM, Sherwin BB. Sex steroids, sexual behavior, and selection attention for erotic stimuli in women using oral contraceptives. Psychoneuroendocrinology 1993; 18: 91-102.
20. European Medicines Agency (EMEA). EPARs for authorised medicinal products for human use. 2007. Available at: http://www.emea.europa.eu/ humandocs/Humans/EPAR/intrinsa/intrinsa.htm (accessed July 20, 2007).
21. Wierman ME, Basson R, Davis SR, Khosla S, Miller KK, Rosner W, Santoro N. Androgen therapy in women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrin Metab 2006; 91: 3697-716.
22. Traish A, Guay AT, Spark RF. Are the Endocrine Society's Clinical Practice Guidelines on Androgen Therapy in Women Misguided? A Commentary. J Sex Med 2007; 4: 1223-35.
23. Park K, Kang HK, Seo JJ, Kim HJ, Ryu SB, Jeong GW. Blood-oxygenation-level-dependent functional magnetic resonance imaging for evaluating cerebral regions of female sexual arousal response. Urology 2001; 57: 1189-94.
24. Karama S, Lecours AR, Leroux JM, Bourgouin P, Beaudoin G, Joubert S, Beauregard M. Areas of brain activation in males and females during viewing of erotic film excerpts. Hum Brain Mapp 2002; 16: 1-13.
25. Gizewski ER, Krause E, Karama S, Baars A, Senf W, Forsting M. There are differences in cerebral activation between females in distinct menstrual phases during viewing of erotic stimuli: A fMRI study. Exp Brain Res 2006; 174: 101-8.
26. Frajese G, Lazzari R, Magnani A, Moretti C, Sforza V, Nerozzi D. Neurotransmitter, opiodergic system, steroid-hormone interaction and involvement in the replacement therapy of sexual disorders. J Steroid Biochem Mol Biol 1990; 37: 411-9.
27. Voisey J, Carroll L, van Daal A. Melanocortins and their receptors and antagonists. Curr Drug Targets 2003; 4: 586-97.
28. Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med 2006; 3: 628-38.